Wilder Talks Payer Landscape and Value With PharmaVoice
Precision for Value’s Kelly Wilder is interviewed by PharmaVoice and provides her perspectives on the payer landscape, the definition of value, and best practices for pharmaceutical companies.
Schafer and Hennessey Address Oncology Care Management in Managed Healthcare Executive
The recent AMCP presentation by Precision for Value’s Jeremy Schafer and Maureen Hennessey, “The Present and Future of Oncology Care Management” is highlighted in the latest edition of Managed Healthcare Executive.
Trends and Projections in Oncology Care Management
Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.
PHE Authors Awarded 2017 JMCP Award for Excellence
Congratulations to PHE authors Joanna MacEwan, Jason Shafrin, and Darius Lakdawalla who, along with coauthors Felicia Forma, Ainslie Hatch, and Jean-Pierre Lindenmayer, have been awarded the 2017 JMCP Award for Excellence.
The JMCP Award for Excellence is an annual award recognizing a single article that represents the best scholarly work in managed care pharmacy. The paper, “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed With Schizophrenia,” brings a cutting-edge statistical technique to the analysis of adherence to serious mental illness medicines.
A Conversation with Dan Renick in Pharmaceutical Commerce
Precision for Value president Dan Renick is interviewed for Pharmaceutical Commerce, providing his in-depth perspective on today’s payer and provider markets.
Commentary: The Challenges of Harmonizing Biomarker Data: Why Trial Success Depends on It
Precision for Medicine’s Scott Marshall and Jared Kohler address the challenges and importance of harmonizing biomarker data in a new editorial for Genetic Engineering and Biotechnology News (GEN). Scott and Jared make the point that generating, tracking, and harmonizing biomarker data and clinical data in real time to inform timely decision-making is critical in modern clinical trials.
Download the New Oncology Research Brief from Precision Health Economics
How is value defined in cancer care? What do patients value most?
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
Jeremy Schafer Addresses Sanofi/Regeneron’s dupilumab in BioPharm Insight
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing
Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Schafer Discusses Hepatitis C Drug Safety Concerns in Drug Topics
Precision for Value’s Jeremy Schafer discusses safety concerns over some hepatitis C drugs in the latest edition of Drug Topics.